HbA1c News and Research

RSS

Most weight lost on GLP-1 drugs returns within a year after stopping

The cessation of GLP-1RAs is linked to a 60% weight regain within a year, emphasizing the importance of tailored strategies for effective long-term weight loss.

9 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with placebo at 4 mg or 6 mg doses. Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

24 Feb 2026

Syzygium jambolanum extract shows promise for diabetes management

The search for effective and accessible therapies for diabetes continues to draw attention to medicinal plants with a long history of traditional use.

19 Feb 2026

Gut microbiome may shape response to GLP-1 drugs, new review suggests

This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how microbial composition may shape treatment response and highlights the need for controlled human studies to enable microbiome-informed precision therapy.

19 Feb 2026

Monthly produce prescriptions do not improve blood sugar

Findings from a study on produce prescriptions show no significant improvement in blood sugar control, emphasizing the importance of addressing food insecurity.

19 Feb 2026

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026

Higher red meat intake links to greater diabetes odds in large US study

Higher intakes of total, processed, and unprocessed red meat were associated with greater odds of diabetes in a nationally representative sample of US adults. Statistical substitution models suggest replacing red meat with plant proteins, poultry, dairy, or whole grains may be linked to lower diabetes odds, though causality cannot be inferred.

15 Feb 2026

Ozempic users continue treatment when weight loss works despite side effects

A study on Ozempic for weight loss reveals user satisfaction is driven by efficacy, despite common gastrointestinal side effects impacting treatment adherence.

13 Feb 2026

Magnesium lower fasting blood sugar in older adults

Magnesium boosts fasting glucose control in older adults with deficiency, but preventing diabetes progression may need more than just mineral correction.

13 Feb 2026

Posture-induced retinal vascular response predicts diabetic retinopathy progression

Diabetic retinopathy develops through complex microvascular damage driven by chronic hyperglycemia, yet traditional risk factors such as disease duration or glycemic control explain only part of individual risk.

11 Feb 2026

Metformin linked to lower odds of intermediate macular degeneration in people with diabetes

A five-year image-based study in people with type 2 diabetes found metformin use was associated with lower odds of developing intermediate age-related macular degeneration. The observational findings suggest a potential protective link but do not establish causation and warrant prospective clinical trials.

4 Feb 2026

Financial incentives improve glycemic control in low-income diabetes patients

A new study examined whether providing financial vouchers to offset medication costs, conditional on improved blood sugar levels, could enhance glycemic control.

3 Feb 2026

Financial incentives lower blood sugar in uncontrolled type 2 diabetes

In this randomized controlled trial in Israel, researchers examined whether a contingent discount as a financial incentive on medication expenses could help people with poorly controlled type 2 diabetes better manage their blood sugar.

27 Jan 2026

When you eat matters: early time-restricted eating improves metabolic health

Time-restricted eating improves several metabolic outcomes compared with usual diets, with benefits observed for body weight, adiposity, blood pressure, insulin, glucose, and triglycerides. Early eating windows consistently outperform late eating, while the optimal duration of food intake remains uncertain.

22 Jan 2026

Lifestyle prevention of diabetes may halve carbon footprint associated with treating complications

Preventing high blood glucose (pre-diabetes) from turning into type 2 diabetes with lifestyle changes could more than halve the carbon footprint associated with treating the complications of the disease, suggests a modelling study, published in the open access journal BMJ Open.

20 Jan 2026